Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.51 Analyst target: $9.91 Upside: 294.82%
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
See the full interactive analysis & chart →Informational only — not investment advice.